2026 Revenue Consensus at $495.28M, Adjusted EBITDA View Lowered to $100M-$107M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy AORT?
2026 revenue consensus $495.28M. Lowers 2026 adjusted EBITDA view to $100M-$107M from $105M-$110M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AORT
Wall Street analysts forecast AORT stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 35.420
Low
40.00
Averages
51.71
High
58.00
Current: 35.420
Low
40.00
Averages
51.71
High
58.00
About AORT
Artivion, Inc. is engaged in manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The Company operates through two segments, which include Medical Devices and Preservation Services. The medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease, including heart valve disease, aortic aneurysms, and dissections, and, to a lesser extent, other conditions in cardiac and vascular surgery. It has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Artivion to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Artivion, Inc. will release its Q1 2026 financial results on May 7, 2026, after market close, providing critical financial and statistical information for investor analysis.
- Teleconference Details: The company will hold a teleconference on the release day at 4:30 p.m. ET, hosted by Chairman and CEO Pat Mackin, aimed at discussing financial results in depth and addressing investor questions.
- Replay Access: A replay of the teleconference will be available approximately one hour after the event, accessible by calling 877-660-6853 or 201-612-7415, with the replay conference number being 13759187, ensuring that investors who missed the live session can still obtain relevant information.
- Company Background: Artivion is a medical device company focused on cardiac and vascular surgery, offering products such as aortic stent grafts and surgical sealants, operating in over 100 countries, and dedicated to providing solutions for the challenges faced by surgeons treating aortic diseases.
See More
Analysis of Stocks Under $50
- Risks of Box: Box (NYSE: BOX) is currently priced at $21.46, and despite its role as a 'Content Cloud' managing 90% of unstructured business data, its average billings growth of 11.9% raises concerns about future demand stability.
- Challenges for Artivion: Artivion (NYSE: AORT) trades at $37.63, and while it operates in the cardiac and vascular device market, its revenue of $441.3 million indicates limited distribution channels, and the lack of free cash flow hampers its reinvestment capabilities.
- Growth Potential of WisdomTree: WisdomTree (NYSE: WT) is priced at $15.84, and with an impressive annual revenue growth of 18.9% and a 52.5% increase in earnings per share, it demonstrates strong market share gains and is expected to continue outperforming the market.
- Stocks to Watch: In the current market environment, investors should focus on stocks that not only have strong fundamentals but are also experiencing upward momentum to seize potential investment opportunities.
See More
Artivion Shares Surge 5.3% on FDA Approval News
- Stock Price Surge: Artivion's shares rose 5.3% in the last trading session to close at $35.22, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's prospects.
- FDA Approval Impact: The FDA's premarket approval for the NEXUS Aortic Arch System allows Artivion to exercise its option to acquire its long-standing partner Endospan within 90 days of receiving this notice, further strengthening the company's market position.
- Earnings Expectations: Artivion is expected to report quarterly earnings of $0.06 per share, unchanged from the year-ago quarter, with revenues projected at $115.95 million, representing a 17.1% increase, indicating growth potential in the medical device sector.
- Market Trend Monitoring: Although the current EPS estimate has remained unchanged over the past 30 days, research shows that trends in earnings estimate revisions are closely correlated with short-term stock price movements, prompting investors to monitor Artivion's future performance closely.
See More
Artivion Receives FDA Approval for NEXUS Aortic Arch System
- FDA Approval Milestone: Artivion announced that its NEXUS Aortic Arch System has received premarket approval from the U.S. FDA, becoming the first branched endovascular stent graft cleared for use, offering a safer alternative to open-chest surgery and marking a significant advancement in the treatment of complex aortic arch disease.
- Clinical Data Support: The NEXUS TRIOMPHE IDE trial demonstrated that 90% of patients avoided lesion-related death, 90% were free from disabling stroke, and 98% avoided reintervention due to endoleaks one year post-treatment, highlighting the clinical value of this technology in a high-risk patient population.
- Global Market Expansion: The FDA approval allows Artivion to promote the NEXUS system in the U.S. market, further enhancing its influence in the global cardiovascular solutions sector while providing broader treatment options for American patients.
- Acquisition Opportunity: The FDA approval entitles Artivion to acquire Endospan Ltd. within 90 days, supported by a $150 million delayed draw term loan, reflecting the company's proactive strategy in investment and market expansion.
See More
Artivion Receives FDA Approval for NEXUS System
- FDA Approval: Artivion's NEXUS Aortic Arch System has received FDA approval, marking a significant advancement in the minimally invasive treatment of aortic arch disease, which is expected to enhance the company's competitiveness in this market.
- Acquisition Option: Following the FDA approval, Artivion has a 90-day window to exercise its option to acquire its partner Endospan, reflecting the company's proactive stance towards future growth opportunities that could strengthen its product portfolio.
- Funding Preparedness: Artivion has a $150 million delayed-draw term loan in place to support a potential acquisition, providing the company with financial flexibility to ensure it is not constrained during the acquisition process.
- Clinical Data Support: The FDA approval of the NEXUS system is backed by data from the NEXUS TRIOMPHE IDE trial, which demonstrated a 90% survival rate and a 98% freedom from reintervention in a high-risk patient population, further validating the product's clinical efficacy and market potential.
See More
Endospan's NEXUS Stent Graft System Approved by FDA for Aortic Arch Disease
- FDA Approval Milestone: Endospan's NEXUS stent graft system has received premarket approval from the FDA, representing a significant breakthrough in treatment options for aortic arch diseases, including chronic aortic dissections, which is expected to greatly enhance patient survival rates and quality of life.
- Acquisition Option Activation: Artivion can exercise its option to acquire Endospan within 90 days of FDA approval, reflecting the company's confidence in future market potential, and has secured a $150 million loan to support this potential acquisition.
- Clinical Data Validation: The NEXUS system demonstrated a 90% patient survival rate, 90% freedom from disabling stroke, and 98% freedom from reintervention due to endoleaks at one year in the TRIOMPHE IDE trial, underscoring its effectiveness and safety in high-risk patient populations.
- Expansive Market Outlook: The approval of NEXUS opens new opportunities for Artivion's market expansion across over 100 countries, particularly in the aortic disease treatment sector, which is anticipated to drive future revenue growth and increase market share.
See More
Artivion to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Artivion, Inc. will release its Q1 2026 financial results on May 7, 2026, after market close, providing critical financial and statistical information for investor analysis.
- Teleconference Details: The company will hold a teleconference on the release day at 4:30 p.m. ET, hosted by Chairman and CEO Pat Mackin, aimed at discussing financial results in depth and addressing investor questions.
- Replay Access: A replay of the teleconference will be available approximately one hour after the event, accessible by calling 877-660-6853 or 201-612-7415, with the replay conference number being 13759187, ensuring that investors who missed the live session can still obtain relevant information.
- Company Background: Artivion is a medical device company focused on cardiac and vascular surgery, offering products such as aortic stent grafts and surgical sealants, operating in over 100 countries, and dedicated to providing solutions for the challenges faced by surgeons treating aortic diseases.
See More
Analysis of Stocks Under $50
- Risks of Box: Box (NYSE: BOX) is currently priced at $21.46, and despite its role as a 'Content Cloud' managing 90% of unstructured business data, its average billings growth of 11.9% raises concerns about future demand stability.
- Challenges for Artivion: Artivion (NYSE: AORT) trades at $37.63, and while it operates in the cardiac and vascular device market, its revenue of $441.3 million indicates limited distribution channels, and the lack of free cash flow hampers its reinvestment capabilities.
- Growth Potential of WisdomTree: WisdomTree (NYSE: WT) is priced at $15.84, and with an impressive annual revenue growth of 18.9% and a 52.5% increase in earnings per share, it demonstrates strong market share gains and is expected to continue outperforming the market.
- Stocks to Watch: In the current market environment, investors should focus on stocks that not only have strong fundamentals but are also experiencing upward momentum to seize potential investment opportunities.
See More
Artivion Shares Surge 5.3% on FDA Approval News
- Stock Price Surge: Artivion's shares rose 5.3% in the last trading session to close at $35.22, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's prospects.
- FDA Approval Impact: The FDA's premarket approval for the NEXUS Aortic Arch System allows Artivion to exercise its option to acquire its long-standing partner Endospan within 90 days of receiving this notice, further strengthening the company's market position.
- Earnings Expectations: Artivion is expected to report quarterly earnings of $0.06 per share, unchanged from the year-ago quarter, with revenues projected at $115.95 million, representing a 17.1% increase, indicating growth potential in the medical device sector.
- Market Trend Monitoring: Although the current EPS estimate has remained unchanged over the past 30 days, research shows that trends in earnings estimate revisions are closely correlated with short-term stock price movements, prompting investors to monitor Artivion's future performance closely.
See More
Artivion Receives FDA Approval for NEXUS Aortic Arch System
- FDA Approval Milestone: Artivion announced that its NEXUS Aortic Arch System has received premarket approval from the U.S. FDA, becoming the first branched endovascular stent graft cleared for use, offering a safer alternative to open-chest surgery and marking a significant advancement in the treatment of complex aortic arch disease.
- Clinical Data Support: The NEXUS TRIOMPHE IDE trial demonstrated that 90% of patients avoided lesion-related death, 90% were free from disabling stroke, and 98% avoided reintervention due to endoleaks one year post-treatment, highlighting the clinical value of this technology in a high-risk patient population.
- Global Market Expansion: The FDA approval allows Artivion to promote the NEXUS system in the U.S. market, further enhancing its influence in the global cardiovascular solutions sector while providing broader treatment options for American patients.
- Acquisition Opportunity: The FDA approval entitles Artivion to acquire Endospan Ltd. within 90 days, supported by a $150 million delayed draw term loan, reflecting the company's proactive strategy in investment and market expansion.
See More
Artivion Receives FDA Approval for NEXUS System
- FDA Approval: Artivion's NEXUS Aortic Arch System has received FDA approval, marking a significant advancement in the minimally invasive treatment of aortic arch disease, which is expected to enhance the company's competitiveness in this market.
- Acquisition Option: Following the FDA approval, Artivion has a 90-day window to exercise its option to acquire its partner Endospan, reflecting the company's proactive stance towards future growth opportunities that could strengthen its product portfolio.
- Funding Preparedness: Artivion has a $150 million delayed-draw term loan in place to support a potential acquisition, providing the company with financial flexibility to ensure it is not constrained during the acquisition process.
- Clinical Data Support: The FDA approval of the NEXUS system is backed by data from the NEXUS TRIOMPHE IDE trial, which demonstrated a 90% survival rate and a 98% freedom from reintervention in a high-risk patient population, further validating the product's clinical efficacy and market potential.
See More
Endospan's NEXUS Stent Graft System Approved by FDA for Aortic Arch Disease
- FDA Approval Milestone: Endospan's NEXUS stent graft system has received premarket approval from the FDA, representing a significant breakthrough in treatment options for aortic arch diseases, including chronic aortic dissections, which is expected to greatly enhance patient survival rates and quality of life.
- Acquisition Option Activation: Artivion can exercise its option to acquire Endospan within 90 days of FDA approval, reflecting the company's confidence in future market potential, and has secured a $150 million loan to support this potential acquisition.
- Clinical Data Validation: The NEXUS system demonstrated a 90% patient survival rate, 90% freedom from disabling stroke, and 98% freedom from reintervention due to endoleaks at one year in the TRIOMPHE IDE trial, underscoring its effectiveness and safety in high-risk patient populations.
- Expansive Market Outlook: The approval of NEXUS opens new opportunities for Artivion's market expansion across over 100 countries, particularly in the aortic disease treatment sector, which is anticipated to drive future revenue growth and increase market share.
See More
